Cargando…
Correction: Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847066/ https://www.ncbi.nlm.nih.gov/pubmed/36652112 http://dx.doi.org/10.1186/s13561-023-00419-w |
| _version_ | 1784871353381289984 |
|---|---|
| author | Liu, Huiqin Wang, Ying He, Qi |
| author_facet | Liu, Huiqin Wang, Ying He, Qi |
| author_sort | Liu, Huiqin |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9847066 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-98470662023-01-19 Correction: Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China Liu, Huiqin Wang, Ying He, Qi Health Econ Rev Correction Springer Berlin Heidelberg 2023-01-18 /pmc/articles/PMC9847066/ /pubmed/36652112 http://dx.doi.org/10.1186/s13561-023-00419-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Liu, Huiqin Wang, Ying He, Qi Correction: Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China |
| title | Correction: Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China |
| title_full | Correction: Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China |
| title_fullStr | Correction: Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China |
| title_full_unstemmed | Correction: Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China |
| title_short | Correction: Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in China |
| title_sort | correction: cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non–small cell lung cancer in china |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9847066/ https://www.ncbi.nlm.nih.gov/pubmed/36652112 http://dx.doi.org/10.1186/s13561-023-00419-w |
| work_keys_str_mv | AT liuhuiqin correctioncosteffectivenessanalysisofsintilimabpluspemetrexedandplatinumversuschemotherapyaloneasfirstlinetreatmentinmetastaticnonsquamousnonsmallcelllungcancerinchina AT wangying correctioncosteffectivenessanalysisofsintilimabpluspemetrexedandplatinumversuschemotherapyaloneasfirstlinetreatmentinmetastaticnonsquamousnonsmallcelllungcancerinchina AT heqi correctioncosteffectivenessanalysisofsintilimabpluspemetrexedandplatinumversuschemotherapyaloneasfirstlinetreatmentinmetastaticnonsquamousnonsmallcelllungcancerinchina |